Mebeverine Uses, Dosage, Side Effects & Safety Guide | IBS Treatment Medicine
Authoritative Clinical Reference
Navigation
DRUG NAME: Mebeverine
Therapeutic Class: Musculotropic Smooth Muscle Relaxant
Subclass: Antispasmodic
Speciality: Gastroenterology
Schedule (India): H
Route(s): Oral
Formulations Available in India:
| Formulation | Strengths Available |
| Mebeverine hydrochloride tablets (immediate-release) | 135 mg |
| Mebeverine hydrochloride extended-release capsules | 200 mg |
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Irritable Bowel Syndrome (IBS) and Functional Bowel Disorders
Immediate-Release Tablets (135 mg):
| Parameter | Recommendation |
| Starting dose | 135 mg orally three times daily |
| Titration | Not applicable |
| Usual maintenance dose | 135 mg orally three times daily |
| Maximum dose | 405 mg/day (135 mg TDS) |
Extended-Release Capsules (200 mg):
| Parameter | Recommendation |
| Starting dose | 200 mg orally twice daily |
| Titration | Not applicable |
| Usual maintenance dose | 200 mg orally twice daily |
| Maximum dose | 400 mg/day (200 mg BD) |
Clinical Notes:
- Administer 20 minutes before meals for optimal effect
- Reassess response after 2 weeks; discontinue if no improvement
- ER formulation may improve compliance with equivalent efficacy
2. Spastic Colitis / Mucous Colitis
| Parameter | Recommendation |
| Starting dose | 135 mg orally three times daily (IR) OR 200 mg orally twice daily (ER) |
| Titration | Not applicable |
| Usual maintenance dose | Same as starting dose |
| Maximum dose | 405 mg/day (IR) or 400 mg/day (ER) |
Clinical Notes:
- Duration guided by clinical response
- Reassess necessity after 4 weeks of therapy
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Notes |
| Biliary colic / Functional biliary dyskinesia (OFF-LABEL) | 135 mg orally 2–3 times daily | Short-term (5–7 days) | Specialist only; based on Indian specialist practice |
Evidence Basis: Indian gastroenterology specialist prescribing practice; limited controlled trial data
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — Mebeverine is not approved for routine paediatric use in India.
Secondary Indications – Paediatrics (Off-label)
Functional Abdominal Pain / IBS in Older Children (OFF-LABEL)
| Age Group | Dose | Maximum Dose | Duration |
| ≥10 years | 135 mg orally twice daily | 270 mg/day | 2–4 weeks; reassess need |
| <10 years | NOT RECOMMENDED | — | — |
Safety Monitoring:
- Monitor for changes in bowel habits
- Assess symptom response at 2 weeks
- Rule out organic pathology before initiating
Age Restriction:
- NOT recommended below 10 years of age except under paediatric gastroenterology specialist supervision
Evidence Basis: Limited paediatric data; Indian paediatric gastroenterology specialist practice
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild-to-moderate impairment | No dose adjustment required |
| Severe impairment (eGFR <30 mL/min) | Use with caution; limited pharmacokinetic data |
| Dialysis | No specific data available |
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment | No specific adjustment required; monitor clinical response |
| Moderate impairment | Use with caution; monitor for adverse effects |
| Severe impairment | Avoid or use with caution under specialist supervision; no pharmacokinetic data available |
CONTRAINDICATIONS
- Known hypersensitivity to mebeverine hydrochloride or any excipients
- Paralytic ileus
- Intestinal obstruction
CAUTIONS
- Organic bowel disease: Rule out structural GI pathology (malignancy, IBD) before initiating empiric therapy
- Chronic constipation: Monitor bowel pattern; not ideal for constipation-predominant IBS
- Elderly patients: Monitor for constipation
- Non-response: Reassess diagnosis if no improvement after 2–4 weeks; may mask progression of underlying conditions
- Lactose intolerance: Some formulations contain lactose as excipient
PREGNANCY
| Aspect | Recommendation |
| Overall safety | Limited human data; animal studies show no teratogenicity |
| Risk category | No definitive classification; not known to be teratogenic |
| First trimester | Generally avoided due to limited data |
| When use may be considered | If benefit outweighs risk; short-term use with specialist advice |
| Preferred alternatives | Non-pharmacological measures first; dicyclomine used cautiously by some Indian obstetricians |
| Monitoring | Fetal growth; maternal GI symptom resolution |
LACTATION
| Aspect | Recommendation |
| Compatibility | Likely compatible; minimal systemic absorption expected |
| Expected drug levels in milk | Low (based on pharmacokinetic profile) |
| Human data | Limited |
| Preferred alternatives | Hyoscine butylbromide if antispasmodic needed |
| Infant monitoring | Feeding adequacy, bowel habits, any GI discomfort |
ELDERLY
| Aspect | Recommendation |
| Starting dose | Same as adults (135 mg TDS or 200 mg ER BD) |
| Titration | Not typically required; may start with twice daily dosing if concerned |
| Key risks | Constipation; reassess necessity periodically |
| Monitoring | Bowel function; symptom response |
| Special notes | No anticholinergic effects — preferred over dicyclomine in elderly; no confusion/falls risk |
MAJOR DRUG INTERACTIONS
None of major clinical significance documented.
- Mebeverine undergoes extensive first-pass metabolism with minimal systemic bioavailability
- No significant CYP-mediated interactions reported
- No QT prolongation risk
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Management |
| Other anticholinergic agents | Theoretical additive effect on GI motility (though mebeverine is not anticholinergic) | Monitor for constipation |
| Loperamide | Potential increased risk of reduced bowel motility | Monitor bowel movement patterns; avoid prolonged concurrent use |
| Opioid analgesics | Additive constipation risk | Ensure adequate hydration and fibre intake |
COMMON ADVERSE EFFECTS
- Nausea
- Headache
- Mild GI discomfort or bloating
- Dizziness
- Constipation (uncommon)
Note: Mebeverine is generally well-tolerated with a low incidence of adverse effects due to minimal systemic absorption.
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Notes |
| Hypersensitivity reactions (urticaria, angioedema, anaphylaxis) | Rare; discontinue immediately; supportive management |
| Severe skin reactions | Very rare; discontinue if rash develops |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Assess for red flag symptoms (weight loss, rectal bleeding, anaemia, family history of GI malignancy); rule out organic pathology |
| After initiation | Symptom response at 2 weeks |
| Long-term | Reassess periodically (every 3–6 months) to avoid unnecessary chronic use; monitor bowel habits |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Formulation |
| Colospa® | Abbott | 135 mg tablets, 200 mg SR capsules |
| Mebex® | Intas | 135 mg tablets |
| Mebaspa® | Macleods | 135 mg tablets |
| Colofac® | Abbott | 135 mg tablets |
| Meva® | Sun Pharma | 135 mg tablets, 200 mg SR |
FDC Products (if relevant):
- Mebeverine + Chlordiazepoxide combinations available for IBS with anxiety component
PRICE RANGE (INR)
| Formulation | Approximate Price |
| 135 mg tablet | ₹3–₹8 per tablet |
| 200 mg ER capsule | ₹8–₹15 per capsule |
- NLEM Status: Not included in NLEM 2022
- NPPA Control: Not price-controlled
- Government supply: Limited; primarily available through private pharmacies
CLINICAL PEARLS
- No anticholinergic effects: Unlike dicyclomine and hyoscine, mebeverine does not cause dry mouth, urinary retention, or CNS effects — making it preferred in elderly, glaucoma, and prostatic hypertrophy patients.
- Rule out red flags first: Always exclude organic pathology (weight loss, bleeding, anaemia, family history of malignancy) before initiating empiric therapy for presumed functional bowel disorder.
- Not ideal for constipation-predominant IBS: Mebeverine does not stimulate motility; consider alternatives or combination therapy for IBS-C.
- Compliance tip: Extended-release 200 mg BD formulation may improve adherence compared to 135 mg TDS.
- Reassess chronic use: If symptoms persist beyond 4 weeks or recur frequently, reassess diagnosis rather than continuing indefinitely.
- Safe in special populations: Low systemic absorption makes it suitable for patients where anticholinergic agents are contraindicated or poorly tolerated.
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO Product Database
- Indian Pharmacopoeia / National Formulary of India
- API Textbook of Medicine, 11th Edition
- AIIMS Drug Formulary
- Indian Gastroenterology Association practice patterns
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.